HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hematologic Outcomes of COVID-19 Patients with and without G6PD Deficiency: A Comparative Study.

AbstractINTRODUCTION:
Patients with multiple comorbidities who have coronavirus disease 2019 (COVID-19) have high morbidity and mortality. Glucose-6-phosphate dehydrogenase (G6PD) deficiency has been shown to have an enhanced effect on coronavirus in an earlier study.
METHODS:
We conducted this comparative observational study to evaluate the effects of COVID-19 disease on G6PD deficiency based on the hematologic parameters, COVID-19-related hospitalizations, and mortality in the state of Qatar between January 2020 and May 2020 at four designated COVID-19 facilities. We identified 41 patients with G6PD deficiency who had documented COVID-19 infection. We compared the results with 241 patients with COVID-19 infection who tested negative for G6PD deficiency.: Results: Comparing the COVID-19 positive G6PD deficient with COVID-19 positive G6PD normal activity showed that G6PD normal group had higher white blood cell count (WBC), absolute neutrophil count (ANC), lymphocytes, eosinophils, and monocytes counts versus the G6PD deficient group (p < 0.001).
CONCLUSIONS:
When compared with COVID-19 patients with normal G6PD, patients with COVID-19 infection and G6PD deficiency had lower total WBC, ANC, lymphocyte, monocyte, and eosinophil counts. However, no evidence of increased hemolysis, thrombosis, morbidity, or mortality was observed in COVID-19 patients with G6PD deficiency.
AuthorsKamran Mushtaq, Ashraf T Soliman, Abdulqadir J Nashwan, Fatima Iqbal, Ahmed A Karawia, Doaa H Ahmed, Yousef M Hailan, Mouhammad J Alawad, Muhammad Abubakar, Mohammadshah I Gul, Fateen Ata, Mohammed N Seijari, Mohammed E Elhadi, Samer J Kaspo, Mohamed A Yassin
JournalQatar medical journal (Qatar Med J) Vol. 2022 Issue 4 Pg. 54 ( 2022) ISSN: 0253-8253 [Print] Qatar
PMID36466438 (Publication Type: Journal Article)
Copyright© 2022 Mushtaq, Soliman, Nashwan, Iqbal, Karawia, Ahmed, Hailan, Alawad, Abubakar, Gul, Ata, Seijari, Elhadi, Kaspo, Yassin, licensee HBKU Press.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: